Loading...
Market
How many new indications will Caplyta be approved for by end of 2025?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
FDA announcements and press releases
Story
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, $132 per Share, Adding Caplyta to Neuroscience Portfolio
Jan 13, 2025, 10:44 AM
Johnson & Johnson has confirmed its acquisition of Intra-Cellular Therapies Inc. for $14.6 billion, paying $132 per share in cash. This deal marks a significant move by Johnson & Johnson to bolster its neuroscience portfolio, adding Intra-Cellular's drug Caplyta, which is approved for treating schizophrenia and bipolar depression. The acquisition comes ahead of the JPM Healthcare conference and follows a patent settlement that cleared the way for the deal. Intra-Cellular, co-founded by Sharon Mates and based on research by Nobel laureate Paul Greengard, had a market cap of about $10 billion before the announcement. The deal is seen as part of a broader trend of large drugmakers reentering the neuroscience field, with Intra-Cellular's Caplyta potentially expanding into treatment for major depressive disorder.
View original story
Similar markets
Decreases by more than 10% • 25%
Increases by more than 10% • 25%
Other • 25%
Remains within 10% of current share • 25%
None • 25%
One • 25%
Three or more • 25%
Two • 25%
Yes • 50%
No • 50%
Two • 25%
None • 25%
One • 25%
Three or more • 25%
31 to 40 • 25%
Less than 20 • 25%
20 to 30 • 25%
More than 40 • 25%
More than 5 new treatments • 25%
0-1 new treatments • 25%
4-5 new treatments • 25%
2-3 new treatments • 25%
Approved in USA only • 25%
Not approved in USA or EU • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
More than 3 trials • 25%
2 trials • 25%
1 trial • 25%
3 trials • 25%